BMS reports four-year data from psoriasis treatment extension trial

Bristol Myers Squibb (BMS) has revealed four-year data from the POETYK PSO long-term extension (LTE) trial of Sotyktu in treating moderate-to-severe plaque psoriasis.

The study followed the Phase III POETYK PSO-1 and POETYK PSO-2 trials, with patients receiving an open-label 6mg dose of Sotyktu daily.